Status: Not yet recruiting
Rademikibart IV for Acute Asthma and COPD Exacerbation
A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation
Participants needed: 40
Trial details
Phase: Phase 2Age: 18-85Biological sex: AllType: InterventionalSponsor: Connect Biopharm LLCUpdated: Jul 15, 2026Locations: 1
Eligibility criteria
Asthma cohort [+9]
Asthma cohort [+40]